Naheed Nazrul
Biographic Data
| ID | 7756728 |
|---|---|
| NAME | Naheed Nazrul |
| GIVEN NAMES | Naheed |
| FAMILY NAME | Nazrul |
| SIGNATURE | NAZRUL N |
| AFFILIATIONS | Child Health Research Foundation |
| ORCID | 0000-0003-3906-3490 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Efficient high-risk human papillomavirus screening through pooled testing
Background: The World Health Organization recommends high-risk human papillomavirus (hrHPV) testing as the primary method for cervical cancer screening. Combining samples in a pool can reduce the expense associated with large numbers of commercially available tests. This study simulated the potential test-saving impact of pooled hrHPV testing using real-world data from two low- and middle-income countries (LMICs). Methods: We simulated a two- and…
The effect of hrHPV prevalence on cervical cancer screening strategies
Our study demonstrates that the hrHPV test + VIA strategy is cost-effective both compared to no screening and VIA + colposcopy screening strategy under the optimal (70%) and realistic (8.7%) uptake scenarios, with greater cost-effectiveness at higher hrHPV prevalence levels. While VIA-based strategy is cheaper, self-sampling hrHPV test-based strategy offers greater health benefits. Implementing hrHPV testing in national screening programs at lowe…
High-risk human papillomavirus testing for underscreened populations
The provided estimates can serve to inform policymakers and researchers in the context of implementing hrHPV-based screening in diverse settings
Investigating feasibility of 2021 WHO protocol for cervical cancer screening in underscreened populations
ClinicalTrials.gov, NCT05234112 . Registered 10 February 2022
No prominent works on this page.
Investigating feasibility of 2021 WHO protocol for cervical cancer screening in underscreened populations
ClinicalTrials.gov, NCT05234112 . Registered 10 February 2022
The effect of hrHPV prevalence on cervical cancer screening strategies
Our study demonstrates that the hrHPV test + VIA strategy is cost-effective both compared to no screening and VIA + colposcopy screening strategy under the optimal (70%) and realistic (8.7%) uptake scenarios, with greater cost-effectiveness at higher hrHPV prevalence levels. While VIA-based strategy is cheaper, self-sampling hrHPV test-based strategy offers greater health benefits. Implementing hrHPV testing in national screening programs at lowe…
High-risk human papillomavirus testing for underscreened populations
The provided estimates can serve to inform policymakers and researchers in the context of implementing hrHPV-based screening in diverse settings
Efficient high-risk human papillomavirus screening through pooled testing
Background: The World Health Organization recommends high-risk human papillomavirus (hrHPV) testing as the primary method for cervical cancer screening. Combining samples in a pool can reduce the expense associated with large numbers of commercially available tests. This study simulated the potential test-saving impact of pooled hrHPV testing using real-world data from two low- and middle-income countries (LMICs). Methods: We simulated a two- and…
Cervical cancer (4 works) · Cervical Cancer and HPV Research (4 works) · Biostatistics (3 works) · Cancer (3 works) · Cervical cancer screening (3 works) · Global Cancer Incidence and Screening (3 works) · Medicine (3 works) · Public health (3 works) · Cervical screening (2 works) · Environmental health (2 works)